Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
CYAD (Celyad Oncology SA) provides a centralized hub for tracking developments in clinical-stage cell therapies and immuno-oncology innovations. This resource aggregates essential updates including trial progress, regulatory milestones, and strategic partnerships critical for evaluating the company's position in cancer treatment research.
Investors and researchers will find curated press releases detailing CYAD's NKR-T cell programs, manufacturing advancements, and collaborative initiatives with institutions like Dartmouth College. The collection emphasizes factual reporting on phase transitions, financial disclosures, and operational updates without speculative commentary.
Content spans clinical trial authorizations, intellectual property developments, and executive leadership changes. Regular updates ensure stakeholders maintain current awareness of CYAD's progress in translating cell-based therapies from laboratory research to clinical applications.
Bookmark this page for streamlined access to verified CYAD developments. Combine periodic reviews with real-time monitoring for comprehensive analysis of the company's evolving role in advanced cancer treatment solutions.
Celyad Oncology has reported its full year 2024 financial results, showing a net loss of €5.8 million (€0.14 per share), improved from €8.5 million loss in 2023. The company's treasury position stands at €4.2 million as of December 31, 2024.
Key operational highlights include advancement of their multiplex miRNA-based shRNA non-gene editing technology to a 5-plex system and development of multispecific NKG2D-based CAR T-cell platform. The company has also re-initiated manufacturing of C-Cath®, an intra-myocardial injection catheter.
Financial metrics show reduced R&D expenses at €3.2 million (down from €4.6 million in 2023) and G&A expenses at €3.2 million (down from €6.0 million). Net cash used in operations decreased significantly to €2.8 million from €15.2 million in 2023. The company projects its current cash position will fund operations into Q3 2025.
Celyad Oncology has published preclinical and clinical data for CYAD-211, their first allogeneic CAR T-cell therapy candidate, in the International Journal of Molecular Science. The study focused on patients with relapsed or refractory multiple myeloma.
The therapy utilizes a novel microRNA-based shRNA technology that interferes with CD3ζ expression in the T-cell receptor complex. Preclinical data demonstrated successful knockdown of CD3ζ and inhibition of TCR-mediated activation both in vitro and in vivo.
The Phase I IMMUNICY-1 clinical trial results showed an overall good safety profile with some clinical responses. Notably, no signs of graft-versus-host disease (GvHD) were observed, validating the technology's effectiveness in preventing this common complication. This non-gene edited approach offers advantages in implementation, safety, efficiency, and the ability to modulate multiple target genes simultaneously.
Celyad Oncology (Euronext: CYAD) announces two poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, November 6-10, 2024. The first poster (Abstract 262) focuses on PSMA/NKG2DL tandem CAR T-cells to improve anti-tumor efficacy against prostate cancer, to be presented on November 9. The second poster (Abstract 1133) discusses efficient and safe modulation of multiple target genes in CAR T-cells using a miRNA-based shRNA platform, to be presented on November 8.
Both posters will be available in the poster hall and virtually to SITC Annual Meeting registrants from November 7 at 10 a.m. ET. The posters will also be archived on Celyad Oncology's website under the 'Scientific Publications' section.
Celyad Oncology (Euronext: CYAD) has appointed Matt Kane as its new Chief Executive Officer, effective October 1st, 2024. Kane brings over 20 years of experience in entrepreneurial, CEO, and board roles, with expertise in genome editing and allogeneic CAR T-cell therapies. His career highlights include:
- Raising over $500M in equity financings
- Forming partnerships valued at over $4B
- Co-founding Precision BioSciences (DTIL) in 2006
- Leading Precision's IPO and development of four allogeneic CAR T therapies
- Recent CEO role at Tune Therapeutics, an epigenetic editing company
Kane's appointment aligns with Celyad's focus on CAR T technology and ambitious plans for growth and development in the oncology space.
Celyad Oncology (CYAD) reported its H1 2024 financial results and business highlights. The company is focusing on research and development, particularly in intellectual property monetization. Key developments include:
1. Proof-of-concept for multiplex shRNA non-gene edited technology and multispecific NKG2D-based CAR T-cell platform.
2. Active participation in scientific conferences and publications in peer-reviewed journals.
3. Re-initiation of C-Cath® manufacturing and commercialization.
4. Cash runway extended until Q3 2025.
Financial highlights:
- R&D expenses: €1.5M (down from €2.1M in H1 2023)
- G&A expenses: €1.7M (down from €3.7M in H1 2023)
- Net loss: €3.0M (€0.07 per share)
- Cash position: €6.2M as of June 30, 2024
FAQ
What is the market cap of CYAD (CYAD)?
